Lattice-tip Versus Irrigated-tip Catheter for Linear Ablation of the Cavotricuspid Isthmus. A Multicenter, Randomized Study.
LINEAR
1 other identifier
interventional
96
1 country
1
Brief Summary
The LINEAR study is designed to compare the procedural efficacy, efficiency and safety of linear radiofrequency ablation of the cavotricuspid istmus using either a standar irrigated-tip ablation catheter or lattice-tip ablation catheter .The primary focus of the acute procedural data analysis will be: Procedural efficacy: This will be evaluated based on the rate of bidirectional CTI block persistence after 60 min waiting period documented by high resolution activation mapping. Furthermore, provocative test with intravenous adenosine infusion will be conducted to exclude dormant CTI conduction. Procedural efficiency: This will be evaluated based on the number of RF lesions delivered, time to achieve bidirectional CTI block, and fluoroscopy exposure time. Procedural safety: The incidence of procedural complications will be recorded.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 16, 2025
CompletedFirst Submitted
Initial submission to the registry
July 4, 2025
CompletedFirst Posted
Study publicly available on registry
July 22, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedAugust 27, 2025
August 1, 2025
7 months
July 4, 2025
August 20, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
The primary procedural endpoint for efficacy will be the achievement of bidirectional CTI block after 60 min waiting period documented by high resolution activation mapping . The primary safety endpoint will be the incidence of procedural complications.
The primary procedural endpoint for efficacy will be the achievement of bidirectional CTI block. After completion of the CTI line, bidirectional block will be confirmed through differential pacing maneuvers followed by activation mapping, performed using the Affera mapping system for Group A and the CARTO mapping system for Group B, respectively. Activation mapping will be repeated 60 minutes after the initial documentation of bidirectional block to assess for its persistence or the presence of spontaneous recovery of CTI conduction. In the absence of spontaneous recovery, a provocative test involving intravenous adenosine infusion will be conducted to evaluate for dormant CTI conduction. During the adenosine infusion and the resultant transient atrioventricular block or sinus pause, bidirectional block will be reassessed using differential pacing maneuvers with the mapping catheter positioned laterally to the ablation line.The incidence of procedural complications will be recorded.
60 minutes
Study Arms (2)
CTI radiofrequency ablation with lattice-tip catheter
ACTIVE COMPARATORPatients undergoing CTI catheter ablation using RF energy delivered by the lattice-tip, dual-energy catheter (Sphere-9, Medtronic).
CTI radiofrequency ablation performed with irrigated-tip catheter
ACTIVE COMPARATORPatients undergoing CTI catheter ablation using RF energy delivered by the irrigated RF catheter (ThermoCool® SmartTouch™, Biosense Webster, USA).
Interventions
Cavotricuspid Isthmus ablation
Eligibility Criteria
You may qualify if:
- patients above 18 years of age undergoing CTI ablation
You may not qualify if:
- Prior right atrium ablation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mitera Hospitallead
Study Sites (1)
Mitera General Hospital
Athens, Attikis, 11523, Greece
Study Officials
- PRINCIPAL INVESTIGATOR
Stylianos Tzeis, MD, PhD, FEHRA
Mitera Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD, FEHRA, Cardiologist - Electrophysiologist
Study Record Dates
First Submitted
July 4, 2025
First Posted
July 22, 2025
Study Start
June 16, 2025
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
August 27, 2025
Record last verified: 2025-08